litlas
Log inCreate account

Jens Bedke

Active 2005–2026

116
Papers
23,550
Citations
47
h-index
106
i10-index

Citations

Citations per year for Jens Bedke2001: 6 citations2006: 1 citations2007: 4 citations2008: 1 citations2009: 4 citations2010: 8 citations2011: 16 citations2012: 11 citations2013: 8 citations2014: 18 citations2015: 12 citations2016: 18 citations2017: 48 citations2018: 72 citations2019: 462 citations2020: 934 citations2021: 1,181 citations2022: 1,215 citations2023: 951 citations2024: 1,784 citations2025: 858 citations2026: 25 citations2002–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,821 citing papers, 20.8% of this breakdownChina: 1,047 citing papers, 12% of this breakdownItaly: 629 citing papers, 7.2% of this breakdownUnited Kingdom: 512 citing papers, 5.9% of this breakdownFrance: 492 citing papers, 5.6% of this breakdownGermany: 460 citing papers, 5.3% of this breakdownJapan: 380 citing papers, 4.3% of this breakdownSpain: 347 citing papers, 4% of this breakdownCanada: 303 citing papers, 3.5% of this breakdownNetherlands: 231 citing papers, 2.6% of this breakdownAustralia: 179 citing papers, 2% of this breakdownSouth Korea: 172 citing papers, 2% of this breakdown
0%20.8%Other 24.8%

Institutions

Fields

  • Medicine79.9%
  • Biochemistry, Genetics and Molecular Biology12.7%
  • Immunology and Microbiology4.7%
  • Engineering0.8%
  • Materials Science0.3%
  • Mathematics0.3%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers14.5%
  • Renal cell carcinoma treatment10.9%
  • Bladder and Urothelial Cancer Treatments8.9%
  • Ferroptosis and cancer prognosis4.7%
  • Urinary and Genital Oncology Studies3.2%
  • Immunotherapy and Immune Responses3.1%
  • Other54.7%

Coauthors

All papers

Open in search
  1. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Robert D. Hawkins, Dmitry Nosov, Frédéric Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Yen‐Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles - New England Journal of Medicine 2019 cited by 3,402

  2. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer - New England Journal of Medicine 2021 cited by 1,746

  3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Authors: Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri - New England Journal of Medicine 2021 cited by 1,761

  4. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

    Authors: Börje Ljungberg, Laurence Albigès, Yasmin Abu‐Ghanem, Jens Bedke, Umberto Capitanio, Saeed Dabestani, Sergio Fernandéz‐Pello, Rachel Giles, Fabian Hofmann, Milan Hora, Tobias Klatte, Teele Kuusk, Thomas Lam, Lorenzo Marconi, Thomas Powles, Rana Tahbaz, Alessandro Volpe, Axel Bex - European Urology 2022 cited by 1,489

  5. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    Authors: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden - New England Journal of Medicine 2024 cited by 914

  6. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri - New England Journal of Medicine 2019 cited by 2,550

  7. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

    Authors: Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Gurkamal Chatta, Yüksel Ürün, Dingwei Ye, Zhisong He, Begoña P. Valderrama, Ja Hyeon Ku, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, M. PATEL, Federico Nasroulah, Matthew D. Galsky - New England Journal of Medicine 2023 cited by 462

  8. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M. Burke, Gurjyot K. Doshi, Delphine Topart, Stéphane Oudard, Hans J. Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F. Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 cited by 746

  9. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

    Authors: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Yohann Loriot, Alejo Rodríguez‐Vida, Ronac Mamtani, Evan Y. Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, D. Cascallar, Mirta Varela, Mauricio Fernández Lazzaro, Diego Kaen, Gabriela Gatica, David Hugo Flores, Agustín Falco, Matias Molina, F. Van Aelst, Christof Vulsteke, Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger and 158 more - The Lancet Oncology 2021 cited by 648

  10. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Authors: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010

  11. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Authors: Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke, Ari David Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel A. Vaena, Marc‐Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta K. Pal, Chikara Οhyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D. Galsky - The Lancet Oncology 2017 cited by 1,744

  12. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

    Authors: Thomas Powles, Elizabeth R. Plimack, Denis Soulières, Tom Waddell, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L. Rhoda Molife, Michael B. Atkins, Brian I. Rini - The Lancet Oncology 2020 cited by 745

  13. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

    Authors: Niklas Klümper, Damian J. Ralser, Jörg Ellinger, Florian Roghmann, Julia Albrecht, Eduard Below, Abdullah Alajati, Danijel Sikic, Johannes Breyer, Christian Bolenz, Friedemann Zengerling, Philipp Erben, Kristina Schwamborn, Ralph M. Wirtz, Thomas Horn, Dora Nagy, Marieta Toma, Glen Kristiansen, Thomas Büttner, Oliver Hahn, Viktor Grünwald, Christopher Darr, Eva Erne, Steffen Rausch, Jens Bedke, Katrin Schlack, Mahmoud Abbas, Stefanie Zschäbitz, Constantin Schwab, Alexander Mustea, Patrick Adam, Andreas Manseck, Bernd Wullich, Manuel Ritter, Arndt Hartmann, Jürgen E. Gschwend, Wilko Weichert, Franziska Erlmeier, Michael Hölzel, Markus Eckstein - Clinical Cancer Research 2022 cited by 205

  14. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

    Authors: Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri - The Lancet Oncology 2022 cited by 307

  15. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    Authors: Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles - The Lancet Oncology 2021 cited by 412

  16. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

    Authors: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, S.H. Park, Sang Joon Shin, D.E. Castellano Gauna, Giuseppe Fornarini, J-R. Li, M. Gumus, Nataliya Mar, S. Narayanan, Xin Yu, Seema Rao Gorla, B.M.S. Homet Moreno van der Heijden - Annals of Oncology 2023 cited by 135

  17. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

    Authors: Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler and 141 more - Journal of Clinical Oncology 2024 cited by 158

  18. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

    Authors: Elizabeth R. Plimack, Thomas Powles, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, B. Yа. Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen‐Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo F. Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini - European Urology 2023 cited by 137

  19. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

    Authors: Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Tom Waddell, Dmitry Nosov, Frédéric Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Raymond S. McDermott, Jens Bedke, Satoshi Tamada, Sterling Wu, Joseph E. Burgents, L. Rhoda Molife, Thomas Powles - Journal of Clinical Oncology 2023 cited by 77

  20. Economic aspects of bladder cancer: what are the benefits and costs?

    Authors: K.D. Sievert, Bastian Amend, Udo Nagele, David Schilling, Jens Bedke, Marcus Horstmann, Jörg Hennenlotter, Stephan Kruck, Arnulf Stenzl - World Journal of Urology 2009 cited by 492

  21. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

    Authors: Steffen Rausch, Christian Schwentner, Arnulf Stenzl, Jens Bedke - Human Vaccines & Immunotherapeutics 2014 cited by 114

  22. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

    Authors: Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, P. Wang, В. Э. Федоров, Robert J. Motzer, Toni K. Choueiri - ESMO Open 2024 cited by 91

  23. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

    Authors: Brian I. Rini, Arnulf Stenzl, Romauld Zdrojowy, М. И. Коган, Mikhail Shkolnik, Stéphane Oudard, Steffen Weikert, Sergio Bracarda, Simon J. Crabb, Jens Bedke, Joerg Ludwig, Dominik Maurer, Regina Mendrzyk, Claudia Wagner, Andrea Mahr, Jens Fritsche, Toni Weinschenk, Steffen Walter, Alexandra Kirner, Harpreet Singh‐Jasuja, Carsten Reinhardt, Tim Eisen - The Lancet Oncology 2016 cited by 216

  24. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

    Authors: Mauricio Burotto, Thomas Powles, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, Peter Wang, Viktor Fedorov, Robert J. Motzer, Toni K. Choueiri - Journal of Clinical Oncology 2023 cited by 47